KELUN PHARMA(002422) 新浪财经·2025-04-01 05:46Core Viewpoint - The Chinese pharmaceutical sector is experiencing significant growth, as evidenced by the strong performance of the CSI Pharmaceutical 50 Index and its constituent stocks, alongside the notable increase in the Pharmaceutical 50 ETF's scale and shares [1][2][3]. Group 1: Market Performance - As of April 1, 2025, the CSI Pharmaceutical 50 Index rose by 3.24%, with key stocks such as Kelun Pharmaceutical increasing by 9.99% and Kanghong Pharmaceutical by 8.10% [1]. - The Pharmaceutical 50 ETF saw a 2.90% increase, with a latest price of 0.57 yuan and a trading volume of 701.37 million yuan, reflecting a turnover rate of 3.16% [1]. Group 2: Fund Growth Metrics - Over the past year, the Pharmaceutical 50 ETF's scale increased by 12.02 million yuan, ranking it in the top half among comparable funds [2]. - In the last six months, the ETF's shares grew by 17 million, also placing it in the top half of its peers [2]. - Since its inception, the ETF achieved a maximum monthly return of 23.45% and an average monthly return of 4.58% during up months [2]. Group 3: Fee Structure and Valuation - The management fee for the Pharmaceutical 50 ETF is 0.50%, and the custody fee is 0.10%, which are among the lowest in its category [3]. - The latest price-to-earnings ratio (PE-TTM) for the CSI Pharmaceutical 50 Index is 25.39, indicating it is at a historical low compared to the past five years [3]. Group 4: Industry Trends - Recent updates from the National Healthcare Security Administration indicate a rapid entry of newly included domestic innovative drugs into the market, with favorable policies supporting the innovative drug sector [3]. - The number of new drug approvals is at a record high, suggesting a recovery in performance for many companies in the sector in 2024 [3]. Group 5: Top Holdings - As of March 31, 2025, the top ten weighted stocks in the CSI Pharmaceutical 50 Index account for 57.69% of the index, with companies like WuXi AppTec and Heng Rui Medicine being significant contributors [4].